Improvements in Work Productivity and Activity Impairment in Ocrelizumab-Treated Patients with RRMS: 2-Year Data from the CASTING Study
Background: The Work Productivity and Activity Impairment (WPAI) questionnaire is a patient-reported outcome that assesses percentage of...
Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire
Background: The validated physician-completed MSProDiscussTM tool facilitates physician-patient interaction in evaluating early signs of...
A Description of Real-World MRI Acquired in Patients with Multiple Sclerosis: Preliminary Insights from FlywheelMS
Background: Magnetic resonance imaging (MRI) in the context of routine care is an important tool that can inform clinical decisions in...
Recently Diagnosed Early-Stage RRMS: Neda, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Background: Early treatment of multiple sclerosis (MS) and rapid onset of therapeutic effect provide long-term benefits on disease...
Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design
Background: Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of adults with relapsing multiple...
International Magnims-CMSC-Naims Consensus Recommendations on the Use of Standardized MRI in MS
Background: Standardized magnetic resonance imaging (MRI) guidelines published in 2015 by the MAGNIMS group and in 2016 by the CMSC are...